These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38994604)

  • 1. The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023.
    Marron L; Mateo-Urdiales A; O'Donnell J; Robinson E; Domegan L
    Euro Surveill; 2024 Jul; 29(28):. PubMed ID: 38994604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.
    Brault A; Hart A; Uribe P; Prado J; San Martín J; Maass A; Canals M
    BMC Infect Dis; 2024 May; 24(1):467. PubMed ID: 38698324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
    Laniece Delaunay C; Mazagatos C; Martínez-Baz I; Túri G; Goerlitz L; Domegan L; Meijer A; Rodrigues AP; Sève N; Ilic M; Latorre-Margalef N; Lazar M; Maurel M; Melo A; Andreu Ivorra B; Casado I; Horváth JK; Buda S; Bennett C; de Lange M; Guiomar R; Enouf V; Mlinaric I; Samuelsson Hagey T; Dinu S; Rumayor M; Castilla J; Oroszi B; Dürrwald R; O'Donnell J; Hooiveld M; Gomez V; Falchi A; Kurecic Filipovic S; Dillner L; Popescu R; Bacci S; Kaczmarek M; Kissling E;
    JAMA Netw Open; 2024 Jul; 7(7):e2419258. PubMed ID: 38949812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
    Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of COVID-19 vaccine to the Omicron variant in children and adolescents: a systematic review and meta-analysis.
    Lu W; Zeng S; Yao Y; Luo Y; Ruan T
    Front Public Health; 2024; 12():1338208. PubMed ID: 38660347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
    Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
    JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Jiménez-Sepúlveda N; Gras-Valentí P; Chico-Sánchez P; Castro-García JM; Ronda-Pérez E; Vanaclocha H; Peiró S; Burgos JS; Ana Berenguer ; Navarro D; Sánchez-Payá J;
    Vaccine; 2024 Jul; 42(19):4011-4021. PubMed ID: 38760269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
    Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Sourri F; Karapanou A; Lemonakis N; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
    Vaccine; 2024 Jun; 42(17):3693-3698. PubMed ID: 38729911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test negative case-control study of COVID-19 vaccine effectiveness for symptomatic SARS-CoV-2 infection among healthcare workers: Zambia, 2021-2022.
    Mweso O; Simwanza J; Malambo W; Banda D; Fwoloshi S; Sinyange N; Yoo YM; Feldstein LR; Kapina M; Mulenga LB; Liwewe MM; Musonda K; Kapata N; Mwansa FD; Agolory S; Bobo P; Hines J; Chilengi R
    BMJ Open; 2023 Dec; 13(12):e072144. PubMed ID: 38072491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Urquidi C; Sepúlveda-Peñaloza A; Valenzuela MT; Ponce A; Menares V; Cortes CP; Benítez R; Santelices E; Anfossi R; Moller A; Santolaya ME
    Vaccine; 2024 Jul; 42(18):3851-3856. PubMed ID: 38749822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.
    Link-Gelles R; Levy ME; Natarajan K; Reese SE; Naleway AL; Grannis SJ; Klein NP; DeSilva MB; Ong TC; Gaglani M; Hartmann E; Dickerson M; Stenehjem E; Kharbanda AB; Han J; Spark TL; Irving SA; Dixon BE; Zerbo O; McEvoy CE; Rao S; Raiyani C; Sloan-Aagard C; Patel P; Dascomb K; Uhlemann AC; Dunne MM; Fadel WF; Lewis N; Barron MA; Murthy K; Nanez J; Griggs EP; Grisel N; Annavajhala MK; Akinseye A; Valvi NR; Goddard K; Mamawala M; Arndorfer J; Yang DH; Embí PJ; Fireman B; Ball SW; Tenforde MW
    JAMA Netw Open; 2023 Mar; 6(3):e232598. PubMed ID: 36920396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.